Robert E. Landry
2017
In 2017, Robert E. Landry earned a total compensation of $4.8M as Senior Vice President, Finance and Chief Financial Officer at Regeneron Pharmaceuticals, a 7% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $482,040 |
|---|---|
| Option Awards | $3,675,566 |
| Salary | $618,000 |
| Other | $19,130 |
| Total | $4,794,736 |
Landry received $3.7M in option awards, accounting for 77% of the total pay in 2017.
Landry also received $482K in non-equity incentive plan, $618K in salary and $19.1K in other compensation.
Rankings
In 2017, Robert E. Landry's compensation ranked 2,010th out of 14,666 executives tracked by ExecPay. In other words, Landry earned more than 86.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,010 out of 14,666 | 86th |
Division Manufacturing | 684 out of 5,770 | 88th |
Major group Chemicals And Allied Products | 182 out of 2,074 | 91st |
Industry group Drugs | 135 out of 1,730 | 92nd |
Industry Pharmaceutical Preparations | 103 out of 1,329 | 92nd |
Source: SEC filing on April 26, 2019.
Landry's colleagues
We found three more compensation records of executives who worked with Robert E. Landry at Regeneron Pharmaceuticals in 2017.
News
Regeneron Pharmaceuticals Executive Vice President and General Manager, Industrial Operations and Product Supply Daniel Van Plew's 2021 pay rises 1% to $8.8M
April 21, 2022
Regeneron Pharmaceuticals CEO Leonard Schleifer's 2020 pay jumps 531% to $135M
April 23, 2021
Regeneron Pharmaceuticals CEO Leonard Schleifer's 2019 pay slips 19% to $21M
April 24, 2020
Regeneron Pharmaceuticals CEO Leonard Schleifer's 2018 pay stays at $27M
April 26, 2019